

chain nodes :

19 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

ring bonds :

1-2 1-12 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 13-14 13-18 14-15
15-16 16-17 17-18

exact/norm bonds :

1-2 1-12 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS

10/780,887

=> d his

(FILE 'HOME' ENTERED AT 10:14:18 ON 19 JAN 2006)

FILE 'REGISTRY' ENTERED AT 10:14:35 ON 19 JAN 2006

L1 STRUCTURE UPLOADED

L2 6 S L1

L3 160 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 10:15:22 ON 19 JAN 2006

L4 20 S L3

=> d ibib abs hitstr total

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1289862 CAPLUS

DOCUMENT NUMBER: 144:31701

TITLE: Preparation of metal complexes of trimeric DOTA-macrocyclic substituted aminoisophthalate trihalophenyl derivatives

INVENTOR(S): Harto, Juan R.; Martin, Jose L.; Platzek, Johannes; Schirmer, Heiko; Weinmann, Hanns-Joachim; Carretero, Jose

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115997	A1	20051208	WO 2005-EP4493	20050422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004026103	A1	20051222	DE 2004-102004026103	20040525
PRIORITY APPLN. INFO.: GI			DE 2004-102004026103A	20040525



AB The preparation is described for metal complexes of trihalobenzene functionalized with three DOTA-like chelating groups (I), where X = bromo or iodo. These complexes are suitable as contrast agents. Thus, the ligand I (X = iodo) was prepared in a multistep procedure and was used to prepare Gd, Dy, Yb and Y complexes.

IT **870475-42-6P 870475-43-7P 870475-44-8P**

870475-45-9P 870475-48-2DP, metal complexes


RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of metal complexes with trihalobenzene functionalized with three DOTA-like chelating groups for use as contrast agents)

RN 870475-42-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A






RN 870475-43-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED







O=




RN 870475-44-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED







O=





RN 870475-45-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 870475-48-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED






IT **870475-46-0P 870475-47-1P**



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of trihalobenzene ligand functionalized ligand with three DOTA-like chelating groups)


RN 870475-46-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED





RN 870475-47-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED







IT **870475-49-3DP**, metal complexes

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of trihalobenzene ligand functionalized with three DOTA-like chelating groups for complexation with metals)

RN 870475-49-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




IT **870475-48-2P**RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation of trihalobenzene ligand functionalized with three DOTA-like
chelating groups for complexation with metals)


RN 870475-48-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A



PAGE 1-B



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1220695 CAPLUS

DOCUMENT NUMBER: 143:471966

TITLE: Macrocyclic-substituted trimer halogen-benzene derivatives

INVENTOR(S): Harto, Juan R.; Martin, Jose L.; Platzek, Johannes; Schirmer, Heiko; Weinmann, Hanns-Joachim; Carretero, Jose

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108379	A1	20051117	WO 2005-EP4319	20050419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

DE 2004-102004023093A 20040505

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to rare earth, Fe and Mn complexes of I (X = Br or I' A1 = CONR1(CH2)nNR2(COCH21NH)mCOCH22K, A2 = NR1COCH22K (R1 and R1 = H, C1-2 alkyl group of monohydroxy C1-2 alkyl group; Z1 and Z2 = H or Me; n = 2-4; m = 0-1; K = 1,4,7,11-tetraazacyclotetradecane-1,4,7-triacetic acid group)) and said complexes are suitable as contrast agents. For example, II (H3L) was prepared in a multi step process starting from 2,4,6-triiodo-5-(methylamino)isophthaloyl dichloride and ethylenediamine, with subsequent reaction with 2-bromopropanoyl bromide, 1,4,7-tris(benzylcarbonyl)-1,4,7,11-tetraazacyclotetradecane with deprotection and reaction with chloroacetic acid. GdL in 58 % yield was prepared from II and Gd2O3.

IT 869339-32-2P 869339-33-3P 869339-34-4P

869339-36-6P 869339-37-7P 869339-40-2P

869339-41-3P 869339-42-4P 869339-44-6P

869339-48-0P 869339-49-1P 869339-50-4P

869339-94-6P 869339-95-7P 869339-96-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation and reactant for preparation of transition metal

tetraazatetradecanetriacetate isophthalic acid amide derivative complexes

as contrast agents)
 RN 869339-32-2 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[[2,4,6-triiodo-5-[methyl[1-oxo-2-[4,7,10-
 tris[(phenylmethoxy) carbonyl]-1,4,7,10-tetraazacyclododec-1-
 yl]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(1-
 methyl-2-oxo-2,1-ethanediyl)]]bis-, hexakis(phenylmethyl) ester (9CI) (CA
 INDEX NAME)


PAGE 1-A






RN 869339-33-3 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[methyl[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]-N,N'-bis[2-[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)







RN 869339-34-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[2,4,6-triiodo-5-[methyl[1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 869339-36-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[[2,4,6-triiodo-5-[methyl[[4,7,10-tris[(phenylmethoxy) carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-1,3-
 phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-
 , hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 869339-37-7 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[2,4,6-triiodo-5-[methyl[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 869339-40-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[[2,4,6-triiodo-5-[[1-oxo-2-[4,7,10-tris[(phenylmethoxy)carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1,3-
 phenylene]bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-
 ethanediyl)]]bis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 869339-41-3 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]-N,N'-bis[2-[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 869339-42-4 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[2,4,6-triiodo-5-[[1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

NAME)

PAGE 1-A




PAGE 1-B




RN 869339-44-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,7-dicarboxylic acid, 4-[2-[methyl[2,4,6-triiodo-3,5-bis[[[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]amino]carbonyl]phenyl]amino]-2-oxoethyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 869339-48-0 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[[2,4,6-triiodo-5-[methyl[1-oxo-2-[4,7,10-
 tris[(phenylmethoxy)carbonyl]-1,4,7,10-tetraazacyclododec-1-
 yl]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-
 2,1-ethanediyl)imino(1-methyl-2-oxo-2,1-ethanediyl)]]bis-,
 hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





RN 869339-49-1 CAPLUS


CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[methyl[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]-N,N'-bis[2-[[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]acetyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 869339-50-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[2,4,6-triiodo-5-[methyl[1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)imino(1-methyl-2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 869339-94-6 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[methyl(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]-N,N'-bis[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B





RN 869339-95-7 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[[2,4,6-triiodo-5-[[[4,7,10-tris[(phenylmethoxy)carbonyl]-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediyylimino(2-oxo-2,1-ethanediyl)]]bis-, hexakis(phenylmethyl) ester
 (9CI) (CA INDEX NAME)

PAGE 1-A







RN 869339-96-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[[2,4,6-triiodo-5-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




IT 869339-23-1P 869339-27-5P 869339-29-7P
869339-93-5P

RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and relaxivity as contrast agents)


RN 869339-23-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 869339-27-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 869339-29-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



PAGE 2-A


I⁻

PAGE 2-B




RN 869339-93-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




PAGE 1-B



PAGE 2-A

 $\circ =$





IT **869339-24-2P 869339-25-3P 869339-26-4P**
869339-28-6P

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as contrast agents)


RN 869339-24-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED







O=




RN 869339-25-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED







O=




RN 869339-26-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED







O=




RN 869339-28-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED





O=



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:14659 CAPLUS

DOCUMENT NUMBER: 142:105998

TITLE: Preparation of optically pure and enriched isomers of DOTA-type chelating ligands, and contrast agents

INVENTOR(S): Amedio, John C.; Caravan, Peter D.; Jacques, Vincent; Zhou, Kevin L.; Levy, Stuart; Kalageropoulos, Shirley; Greenfield, Matthew

PATENT ASSIGNEE(S): Epix Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005001415	A2	20050106	WO 2004-US16029	20040520
WO 2005001415	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:

US 2003-473369P P 20030523

OTHER SOURCE(S): MARPAT 142:105998

GI



I

AB The preparation of organic chelating ligands, organic chelating ligand precursors,

and metal chelates is described, including methods for preparing optically-enriched or optically-pure compns. designed for use as MRI contrast agents. Thus, in one example, the gadolinium complex with a glutamic acid-DOTA derivative (I) was prepared


IT **817562-99-5P**

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of gadolinium complexes with chiral peptide linked or chiral diacid derivatized DOTA derivs. designed as MRI contrast agents)

RN 817562-99-5 CAPLUS

CN Gadolinate(1-), [α -[3-oxo-3-(pentafluorophenoxy)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7,.ka ppa.O10]-, hydrogen (9CI) (CA INDEX NAME)



● H⁺

IT **817562-91-7P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of gadolinium complexes with chiral peptide linked or chiral diacid derivatized DOTA derivs. designed as MRI contrast agents)

RN 817562-91-7 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, α -[3-oxo-3-(pentafluorophenoxy)propyl]-, tetrakis(1,1-dimethylethyl) ester, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112839	A2	20041229	WO 2004-IB2193	20040617
WO 2004112839	A3	20050506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

AB The invention relates to novel compds. and pharmaceutical compns. that are useful for the diagnosis of many pathologies, in particular cardiovascular, cancer-related and inflammatory pathologies. These compds. comprise a component for targeting a pathol. region linked to a detection component which is effective in diagnostic terms. The detection component is typically an MRI contrast agent, an X-ray contrast agent, or an entity containing a radioisotope or able to be detected by ultrasound or by optical imaging. Compds. Bx-Lz-(HR Ch)y (B is a biovector, L is a linker, HR Ch is a chelate, and x, y, z are 1-8), and their salts with pharmaceutically-acceptable acids or bases, are claimed. Thus, a gadolinium-complexed 1,4,7,10-tetraazacyclododecane derivative was prepared and coupled with peptide H-Pro-Leu-Gly-NHOH. A bis-folate derivative shows very good molar relaxivity (53 mM⁻¹s⁻¹ at 60 MHz).


RN 596121-92-5 CAPLUS
CN Gadolinium, [[1,1',1'',1''',1'''',1'''''',1''''''',1''''''',1''''''',1''''''',1''''''',
''''',1''''''',1''''''']-[13-(3-aminopropyl)-3,6,9,15-
tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-
κN3,κN6,κN9,κN15]tris[[4-(carboxy-κO)-1-oxo-
4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-

benzenetriyl)bis(carbonylnitrilo)]dodecakis[1-deoxyhexitolato]](3-)]-(9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A






IT 596121-90-3P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

```
(preparation of peptidyl gadolinium contrast agents having specific
high-relaxivity)
```


RN 596121-90-3 CAPLUS

CN Gadolinium, [[{1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''',1'''''}
 ''',1''''''''',1''''''''']-[[13-[3-[[(1,1-dimethylethoxy) carbonyl] amino
]propyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-
 triyl-κN3,κN6,κN9,κN15]tris[[4-(carboxy-κO)-
 1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-
 benzenetriyl)bis(carboxylnitrilo)]dodecakis[1-deoxyhexitolato]](3-)]-
 (9CI) (CA INDEX NAME)






PAGE 2-A



PAGE 2-B



~~D4~~ ANSWER 5 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1045347 CAPLUS

DOCUMENT NUMBER: 142:172763

TITLE: Conjugation of DOTA Using Isolated Phenolic Active Esters: The Labeling and Biodistribution of Albumin as Blood Pool Marker

AUTHOR(S): Mier, Walter; Hoffend, Johannes; Kraemer, Susanne; Schuhmacher, Jochen; Hull, William E.; Eisenhut, Michael; Haberkorn, Uwe

CORPORATE SOURCE: Department of Nuclear Medicine, Universitaetsklinikum Heidelberg, Heidelberg, 69120, Germany

SOURCE: Bioconjugate Chemistry (2005), 16(1), 237-240

CODEN: BCCHE5; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB A convenient method for the functionalization of proteins with DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) has been developed. For this purpose DOTA was converted into a series of different monoreactive activated phenolic esters. The esters were prepared in a single step from com. available DOTA, using 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide or 1,3-dicyclohexylcarbodiimide as coupling agent. The resulting activated esters were isolated by HPLC, lyophilized, and stored for future applications. In solid form the compds. exhibit high hydrolytic stability. The reactions with proteins proceeded in good yields. The conjugation and subsequent radiolabeling of the 4-nitrophenol ester of DOTA with ⁶⁷Ga was investigated with rat serum albumin. A time-dependent biodistribution study in tumor bearing rats was conducted to demonstrate the integrity of the albumin conjugate. These results suggest that phenolic esters of DOTA represent versatile reagents to conjugate DOTA with proteins and other biomols. in high yields.

IT 508172-22-3P 834870-36-9P 834870-39-2P
834870-41-6P

RL: BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenolic esters of DOTA represent versatile reagents to conjugate DOTA with proteins)


RN 508172-22-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
mono(2,3,5,6-tetrafluorophenyl) ester (9CI) (CA INDEX NAME)




RN 834870-36-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
mono(2,3,5-trifluorophenyl) ester (9CI) (CA INDEX NAME)




RN 834870-39-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
mono(pentafluorophenyl) ester (9CI) (CA INDEX NAME)



RN 834870-41-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
mono(2,3,4,6-tetrachlorophenyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

X ANSWER 6 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:877920 CAPLUS
 DOCUMENT NUMBER: 141:380135
 TITLE: Preparation of amino acid derivatives in simultaneous
 imaging of cardiac perfusion and a vitronectin
 receptor targeted imaging agent
 INVENTOR(S): Carpenter, Alan P.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 160 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004208823	A1	20041021	US 2002-214429	20020807
US 6838074	B2	20050104		
PRIORITY APPLN. INFO.:			US 2001-310761P	P 20010808
OTHER SOURCE(S):	MARPAT	141:380135		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention describes a method of concurrent imaging in a mammal
 comprising: (a) administering a vitronectin receptor targeted imaging
 agent and a perfusion imaging agent, (b) concurrently detecting the
 vitronectin receptor targeted imaging agent bound at the vitronectin
 receptor and the perfusion imaging agent, and (c) forming an image from
 the detection of the vitronectin targeted imaging agent and the perfusion
 imaging agent. Compds. claimed include those of formula (Q)d-Ln-Ch, where
 Q is a condensed pyrazole derivative or a peptide, d is 1-10, Ln is a linking
 group, and Ch is a metal bonding unit. Thus, L-cysteic acid-derived
 compound (I) bis(trifluoroacetate) was prepared and complexed with indium-111.

IT **277330-12-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino acid derivs. in simultaneous imaging of cardiac
 perfusion and a vitronectin receptor targeted imaging agent)

RN 277330-12-8 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid,
 tris(1,1-dimethylethyl) 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX
 NAME)





REFERENCE COUNT:

91

THERE ARE 91 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:718526 CAPLUS
 DOCUMENT NUMBER: 141:243575
 TITLE: Preparation of 1,3,5-trihalo-2,4,6-benzenetricarboxamide N,N,N-tristetraazacyclododecane metal complexes and related compounds as contrast media.
 INVENTOR(S): Platzek, Johannes; Weinmann, Hanns-Joachim; Schirmer, Heiko; Martin, Jose Luis; Harto, Juan R.; Riefke, Bjoern
 PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074267	A1	20040902	WO 2003-EP14149	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG DE 10307759 B3 20041118 DE 2003-10307759 20030219 CA 2516467 AA 20040902 CA 2003-2516467 20031212 EP 1594851 A1 20051116 EP 2003-782386 20031212 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 2004265236 A1 20041230 US 2004-780887 20040219 PRIORITY APPLN. INFO.: DE 2003-10307759 A 20030219 US 2003-452053P P 20030306 WO 2003-EP14149 W 20031212 OTHER SOURCE(S): MARPAT 141:243575 GI				



AB Title compds. [I; Hal = Br, iodo; A1 = CONR1(CH2)nNR2(COCHZ1NH)mCOCHZ2K,

CONR1(CH2)p(CONR2CH2)mCH(OH)CH2K, CH2O(CH2)pCH(OH)CH2K, CH2O(CH2)nNR1(COCHZ1NH)mCOCHZ2K, CH2NR1CO(CHZ1NHCO)mCHZ2K; A2 = A1, NR1CO(NR1)m(CH2)pNR2(COCHZ1NH)mCOCHZ1K; R1, R2 = H, alkyl, hydroxyalkyl; Z1, Z2 = H, Me; n = 2-4; m = 0, 1; p = 1-4; K = Q1; X = H, metal ion of element nos. 20-29, 39, 42, 44, 57-83; ≥ 2 X = metal ions], were prepared Thus, 2,4,6-triiodo-1,3,5-benzenetricarbonyl trichloride in THF was added to ethylenediamine in THF over 1 h followed by stirring for 14 h to give 70% 2,4,6-triiodo-1,3,5-benzenetricarboxylic acid tris(2-aminoethyl)amide. This was added to a mixture prepared from the Gd complex of 10-[4-carboxy-1-methyl-2-oxo-3-azabutyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, DCC, and N-hydroxysuccinimide in Me2SO to give 73% 2,4,6-triiodo-1,3,5-benzenetricarboxylic acid N,N,N-tris-[3,6-diaza-4,7-dioxo-8-methyloctan-1,8-diyl-[10-[1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane, Gd complex]]]amide. The latter was used for CT imaging of rat blood vessels and kidneys.

IT 753020-30-3P 753020-31-4P 753020-32-5P
753020-33-6P 753020-34-7P 753020-35-8P
753020-36-9P 753020-37-0P 753020-39-2P
753020-40-5P 753020-42-7P 753020-43-8P
753020-44-9P 753020-45-0P 753020-46-1P
753020-49-4P 753020-51-8P 753020-53-0P
753020-56-3P 753020-59-6P 753020-61-0P
753020-63-2P 753020-65-4P


RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)



(preparation of trihalobenzenetricarboxamide tristetraazacyclododecane metal complexes and related compds. as contrast media)

RN 753020-30-3 CAPLUS

CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)imino[1-methyl-2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kappa a.N10, κ O1, κ O4, κ O7]](9-))]tri- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A



PAGE 2-B




PAGE 3-B


RN 753020-31-4 CAPLUS

CN Gadolinium, $[\mu^3-[[10,10',10''-(2,4,6\text{-triiodo-1,3,5-benzenetriyl})\text{tris}[\text{carbonylimino-2,1-ethanediylimino}(2\text{-oxo-2,1-ethanediyl})\text{imino}[2-(\text{oxo-}\kappa\text{O})-2,1\text{-ethanediyl}]]]\text{tris}[1,4,7,10\text{-tetraazacyclododecane-1,4,7-triacetato-}\kappa\text{N1},\kappa\text{N4},\kappa\text{N7},\kappa\text{O1},\kappa\text{O4},\kappa\text{O7}]](9-)]\text{tri-}(9\text{CI})$ (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C




PAGE 2-A

O=




RN 753020-32-5 CAPLUS
 CN Yttrium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



PAGE 2-A

O=


PAGE 2-B




RN 753020-33-6 CAPLUS

CN Gadolinium, [μ^3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,.kappaappa.O7]](9-)]tri- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



PAGE 2-A


O=

PAGE 2-B




RN 753020-34-7 CAPLUS


CN Gadolinium, [μ_3 -[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carboxylimino[2-(hydroxy- κ O)-3,1-propanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)



PAGE 1-B




PAGE 2-A




RN	753020-35-8	CAPLUS
CN	Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonyl(methylimino)[2-(hydroxy- κ O)-3,1-propanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri-(9CI) (CA INDEX NAME)	


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 753020-36-9 CAPLUS
 CN Gadolinium, [μ^3 -[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneoxy[2-(hydroxy- κ O)-3,1-propanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 753020-37-0 CAPLUS
 CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino(1-oxo-2,1-ethanediyl)imino[2-(hydroxy- κ O)-3,1-propanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,.kappa.appa.O7]](9-)]tri- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




PAGE 2-A

 $\text{O}=\text{C}$




RN 753020-39-2 CAPLUS


CN Yttrium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)



PAGE 1-B




PAGE 2-A




RN 753020-40-5 CAPLUS
 CN Gadolinium, [μ_3 -[[10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino[1-methyl-2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B





PAGE 2-A




RN 753020-42-7 CAPLUS
 CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)imino[1-methyl-2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,.kappa.07]](9-)]tri- (9CI) (CA INDEX NAME)

PAGE 1-A







O=




RN 753020-43-8 CAPLUS

CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)imino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,.kappaappa.07]](9-))]tri- (9CI) (CA INDEX NAME)







O=




RN 753020-44-9 CAPLUS

CN Gadolinium, [μ^3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneoxy-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]] (9-)]tri- (9CI) (CA INDEX NAME)






O=




RN 753020-45-0 CAPLUS

CN Gadolinium, [μ_3 -[[10,10'-[[2,4,6-triiodo-5-[[[1-(oxo- κ O)-2-[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]propyl]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)imino[2-(oxo- κ O)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kappa a.N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)




PAGE 1-B




PAGE 2-A

○




RN 753020-46-1 CAPLUS
 CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[imino(2-oxo-2,1-ethanediyl)imino(2-oxo-2,1-ethanediyl)imino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kappa a.N10, κ O1, κ O4, κ O7]](9-))]tri- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 1-C





PAGE 2-A






RN 753020-49-4 CAPLUS
 CN Gadolinium, [μ_3 -[[10,10'-[[2,4,6-triiodo-5-[[[[[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino{2-(oxo- κ O)-2,1-ethanediyl}]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kappa a.N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)







O=




RN 753020-51-8 CAPLUS

CN Gadolinium, [μ 3-[[10,10'-[[2,4,6-triiodo-5-[[[1-(oxo- κ O)-2-[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]propyl]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[1-methyl-2-(oxo- κ O)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)







O=




RN 753020-53-0 CAPLUS

CN Gadolinium, [μ_3 -[[10,10'-[[2,4,6-triiodo-5-[methyl[[[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl- κ O]amino]acetyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7,.kappa a.N10, κ O1, κ O4, κ O7]](9-))]tri- (9CI) (CA INDEX NAME)








O=




RN 753020-56-3 CAPLUS


CN Gadolinium, [μ^3 -[[10,10'-[[2,4,6-triiodo-5-[[[2-[[[4,7,10-tris[(carboxy- κ O)methyl]-1,4,7,10-tetraazacyclododec-1-yl- κ N1, κ N4, κ N7, κ N10]acetyl]amino]ethyl]amino]carbonyl]amino]-1,3-phenylene]bis[carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]bis[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4,.kappa]appa.07]](9-)]tri- (9CI) (CA INDEX NAME)









RN 753020-59-6 CAPLUS
 CN Gadolinium, [μ^3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]](9-)]tri- (9CI) (CA INDEX NAME)







O=




RN 753020-61-0 CAPLUS

CN Dysprosium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]] (9-)]tri- (9CI) (CA INDEX NAME)








O=



RN 753020-63-2 CAPLUS


CN Gadolinium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]] (9-)]tri- (9CI) (CA INDEX NAME)







RN 753020-65-4 CAPLUS
 CN Dysprosium, [μ_3 -[[10,10',10''-(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino[2-(oxo- κ O)-2,1-ethanediyl]]]tris[1,4,7,10-tetraazacyclododecane-1,4,7-triacetato- κ N1, κ N4, κ N7, κ N10, κ O1, κ O4, κ O7]] (9-)]tri- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





IT 752252-80-5P 752252-81-6P 752252-82-7P
 752252-83-8P 752252-84-9P 752252-85-0P
 752252-88-3P 752252-89-4P 752252-92-9P
 752252-93-0P 752252-95-2P 752252-96-3P
 752252-98-5P 752252-99-6P 752253-02-4P
 752253-03-5P 752253-04-6P 752253-06-8P
 752253-07-9P 752253-08-0P 752253-10-4P
 752253-11-5P 752253-13-7P 752253-14-8P
 752253-17-1P 752253-18-2P 752253-19-3P
 752253-22-8P 752253-23-9P 752253-24-0P
 752253-25-1P 752253-26-2P 752253-27-3P
 752253-30-8P 752253-31-9P 752253-32-0P
 752253-34-2P 752253-35-3P 752253-36-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of trihalobenzenetricarboxamide tristetraazacyclododecane metal complexes and related compds. as contrast media)


RN 752252-80-5 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl))]tris-, nonakis(phenylmethyl) ester
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




PAGE 1-C

—CH₂—Ph

PAGE 2-A




PAGE 2-B




RN 752252-81-6 CAPLUS

CN 1,3,5-Benzenetricarboxamide, 2,4,6-triiodo-N,N',N''-tris[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 752252-82-7 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl))]tris- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A







RN 752252-83-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl) tris[carbonylimino-2,1-
 ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]] tris-,
 nonakis(phenylmethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




PAGE 1-C

-CH₂-Ph



PAGE 2-A






RN 752252-84-9 CAPLUS

CN 1,3,5-Benzenetricarboxamide, 2,4,6-triiodo-N,N',N''-tris[2-[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 752252-85-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl))]tris- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752252-88-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10'''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino(2-hydroxy-3,1-propanediyl))]]tris-, nonakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752252-89-4 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino(2-hydroxy-3,1-propanediyl))]]tris- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752252-92-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonyl(methylimino)(2-hydroxy-3,1-propanediyl))]]tris-, nonakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 2-A






RN 752252-93-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10'''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonyl(methylimino)(2-hydroxy-3,1-propanediyl))]tris- (9CI) (CA INDEX NAME)




triiodo-1,3,5-benzenetriyl) tris[methyleneoxy(2-hydroxy-3,1-propanediyl)]] tris- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752252-98-5 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl) tris[carbonylimino(1-oxo-2,1-ethanediyl) imino(2-hydroxy-3,1-propanediyl)]] tris-, nonakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B




RN 752252-99-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(carbonylimino(1-oxo-2,1-ethanediyl)imino(2-hydroxy-3,1-propanediyl))]tris- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




PAGE 1-C

- CO₂H


PAGE 2-A


HO₂C-CH₂-




RN 752253-02-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl) tris[methyleneimino(2-oxo-
2,1-ethanediyl)]] tris-, nonakis(phenylmethyl) ester (9CI) (CA INDEX NAME)






CH_2Ph




RN 752253-03-5 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1-acetamide, N,N',N''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(methylene)]tris- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752253-04-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)]]tris-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752253-06-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl) tris[methyleneimino(1-methyl-2-oxo-2,1-ethanediyl)]] tris-, nonakis(phenylmethyl) ester (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—CH₂—Ph


PAGE 2-A




RN 752253-07-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1-acetamide, N,N',N''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(methylene)]tris[α-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752253-08-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(methyleneimino(1-methyl-2-oxo-2,1-ethanediy))]]tris- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 752253-10-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)imino(1-methyl-2-oxo-2,1-ethanediyl)]]tris-, nonakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A







RN 752253-11-5 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)imino(1-methyl-2-oxo-2,1-ethanediyl)]]tris- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752253-13-7 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneimino(2-oxo-2,1-ethanediyl)imino(2-oxo-2,1-ethanediyl)]]tris-, nonakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




PAGE 1-C

—OBu-t


PAGE 2-A






RN 752253-14-8 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[imino(2-oxo-2,1-ethanediyl)imino(2-oxo-2,1-ethanediyl)]]tris- (9CI) (CA INDEX NAME)




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752253-17-1 CAPLUS
 CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneoxy-2,1-
 ethanediylimino(2-oxo-2,1-ethanediyl)]]tris-, nonakis(phenylmethyl) ester
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




PAGE 1-C

—CH₂—Ph

PAGE 2-A




PAGE 2-B




RN 752253-18-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1-acetamide, N,N',N''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris(methyleneoxy-2,1-ethanediyl)]tris- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 752253-19-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10',10''-[(2,4,6-triiodo-1,3,5-benzenetriyl)tris[methyleneoxy-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]tris- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A







RN 752253-22-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[(2,4,6-triiodo-5-[[[[[4,7,10-tris[(phenylmethoxy)carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-
 phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-
 , hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752253-23-9 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[[[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]acetyl]amino]-N,N'-bis[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 752253-24-0 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediyl]limino(2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A







RN 752253-25-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[(2,4,6-triiodo-5-[[[1-oxo-2-[4,7,10-tris[(phenylmethoxy)carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]acetyl]amino]-1,3-
 phenylene)bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-
 ethanediyl)]]bis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 752253-26-2 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]acetyl]amino]-N,N'-bis[2-[[1-oxo-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 752253-27-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[1-oxo-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(1-methyl-2-oxo-2,1-ethanediyl)]]bis- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A




—CO₂H


RN 752253-30-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[(2,4,6-triiodo-5-[methyl[[[4,7,10-tris[(phenylmethoxy)carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-
 phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-
 , hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 752253-31-9 CAPLUS

CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-5-[methyl[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]acetyl]amino]-N,N'-bis[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A





RN 752253-32-0 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[methyl[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]acetyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-(9CI) (CA INDEX NAME)




RN 752253-34-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-tricarboxylic acid,
 10,10'-[(2,4,6-triiodo-5-[[[2-[[[4,7,10-tris[(phenylmethoxy)carbonyl]-
 1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]amino]-
 1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-
 ethanediyl)]]bis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A

O
||


PAGE 1-B




PAGE 1-C




PAGE 2-A






RN 752253-35-3 CAPLUS


CN 1,3-Benzenedicarboxamide, 2,4,6-triiodo-N,N'-bis[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]-5-[[[2-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]ethyl]amino]carbonyl]amino]- (9CI)
(CA INDEX NAME)



PAGE 1-B




PAGE 2-A




RN 752253-36-4 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10,10'-[(2,4,6-triiodo-5-[[[2-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]ethyl]amino]carbonyl]amino]-1,3-phenylene)bis[carbonylimino-2,1-ethanediylimino(2-oxo-2,1-ethanediyl)]]bis-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



REFERENCE COUNT:


4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

X ANSWER 8 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:543760 CAPLUS
 DOCUMENT NUMBER: 141:207367
 TITLE: Synthesis, Characterization, and Optical Properties of
 Pentafluorophenyl Complexes with a Pt-Cd Bond
 AUTHOR(S): Fornies, Juan; Ibanez, Susana; Martin, Antonio; Gil,
 Belen; Lalinde, Elena; Moreno, M. Teresa
 CORPORATE SOURCE: Departamento de Quimica Inorganica, CSIC, Instituto de
 Ciencia de Materiales de Aragon, Universidad de
 Zaragoza, Zaragoza, 50009, Spain
 SOURCE: Organometallics (2004), 23(16), 3963-3975
 CODEN: ORGND7; ISSN: 0276-7333
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:207367
AB Novel bimetallic neutral [(C6F5)4PtCd(cyclen)] (1) and
 [(C6F5)2(C.tplbond.CPh)2PtCd(cyclen)] (2) and cationic
 [(C6F5)2(bzq)PtCd(cyclen)](ClO4) (3) pentafluorophenylplatinum(II)-
 cadmium(II) derivs. have been prepared by treatment of the anionic starting
 precursors [Pt(C6F5)2X2]n- (n = 2, X = C6F5, C.tplbond.CPh; n = 1, X2 =
 bzq) with Cd(ClO4)2 and cyclen. X-ray diffraction studies on complexes 1,
 2, and 3 show that they are stabilized by a short Pt→Cd donor
 acceptor bond and, addnl., in complex 2 the Cd center is also coordinated
 to the Cα of one of the two alkynyl groups. In contrast, treatment
 of the binuclear compound [NBu4]2[Pt2(μ-Cl)2(C6F5)4] with
 [Cd(cyclen)(MeOH)2](ClO4)2 afforded the tetranuclear derivative
 [Pt(C6F5)2Cl(μ-Cl)Cd(cyclen)]2 (4), in which Pt and Cd atoms are
 connected by a μ3-Cl bridging ligand, and the binuclear cadmium complex
 [Cd2(μ-Cl)2(cyclen)2](ClO4)2 (5), in which two "Cd(cyclen)" fragments
 are bridged by two chlorine atoms. The structures of 4 and 5 were
 established via x-ray diffraction. The photoluminescent properties of
 complexes 1-3 have also been examined and compared with those of their
 corresponding anionic parent compds. [NBu4]2[Pt(C6F5)4],
 [PMePh3]2[Pt(C6F5)2(C.tplbond.CPh)2], and [NBu4][Pt(C6F5)2(bzq)] (6).
IT **741272-51-5P**
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP
 (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC
 (Process)
 (crystal structure, luminescence; preparation, structure, and optical
 properties of pentafluorophenyl complexes with a Pt-Cd bond)
RN 741272-51-5 CAPLUS
CN Platinum, bis(pentafluorophenyl)[μ-(phenylethynyl)](phenylethynyl)[(1,4
 ,7,10-tetraazacyclododecane-κN1,κN4,κN7,κN10)cadmi
 um]-, (Cd-Pt), compd. with 2-propanone (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 741272-39-9
CMF C36 H30 Cd F10 N4 Pt
CCI CCS



CM 2

CRN 67-64-1

CMF C3 H6 O



IT 741694-38-2P 741694-39-3P 741694-51-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (crystal structure; preparation, structure, and optical properties of
 pentafluorophenyl complexes with a Pt-Cd bond)

RN 741694-38-2 CAPLUS

CN Platinum, tetrakis(pentafluorophenyl)[(1,4,7,10-tetraazacyclododecane-
 κN1,κN4,κN7,κN10)cadmium]-, (Cd-Pt), stereoisomer,
 compd. with 2-propanone (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 741272-37-7


CMF C32 H20 Cd F20 N4 Pt


CCI CCS

PAGE 1-A



PAGE 2-A






CM 2

CRN 67-64-1

CMF C3 H6 O




RN 741694-39-3 CAPLUS

CN Platinum, (benzo[h]quinolin-10-yl-κC10,κN1)bis(pentafluorophenyl)[(1,4,7,10-tetraazacyclododecane-κN1,κN4,κN7,κN10)cadmium]-, (Cd-Pt), stereoisomer, perchlorate, compd. with methanol (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 67-56-1

CMF C H4 O



CM 2


CRN 741272-41-3

CMF C33 H28 Cd F10 N5 Pt . Cl O4


CM 3

CRN 741272-40-2
 CMF C33 H28 Cd F10 N5 Pt
 CCI CCS

PAGE 1-A




PAGE 2-A



CM 4




CRN 14797-73-0
 CMF Cl O4




RN 741694-51-9 CAPLUS
 CN Platinum, di-μ3-chlorodichlorotetrakis(pentafluorophenyl)bis[(1,4,7,10-tetraazacyclododecane-κN1,κN4,κN7,κN10)cadmium]di-, stereoisomer, compd. with 2-propanone (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 741272-43-5
 CMF C40 H40 Cd2 Cl4 F20 N8 Pt2



PAGE 3-A




PAGE 4-A



CM 2

CRN 67-64-1
CMF C3 H6 O




IT 741272-39-9P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(mol. structure, UV, fluxionality, activation free energy; preparation, structure, and optical properties of pentafluorophenyl complexes with a Pt-Cd bond)

RN 741272-39-9 CAPLUS

CN Platinum, bis(pentafluorophenyl) [μ-(phenylethynyl)] (phenylethynyl) [(1,4,7,10-tetraazacyclododecane-κN1,κN4,κN7,κN10) cadmium]-, (Cd-Pt) (9CI) (CA INDEX NAME)



IT 741272-37-7P 741272-41-3P


RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(mol. structure, UV, luminescence; preparation, structure, and optical properties of pentafluorophenyl complexes with a Pt-Cd bond)


RN 741272-37-7 CAPLUS

CN Platinum, tetrakis(pentafluorophenyl)[(1,4,7,10-tetraazacyclododecane-κN1,κN4,κN7,κN10)cadmium]-, (Cd-Pt), stereoisomer (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



PAGE 3-A




RN 741272-41-3 CAPLUS
 CN Platinum(1+), (benzo[h]quinolin-10-yl- κ C, κ N)bis(pentafluorophenyl)[(1,4,7,10-tetraazacyclododecane- κ N1, κ N4, κ N7, κ N10)cadmium]-, (Cd-Pt), stereoisomer, perchlorate (9CI) (CA INDEX NAME)


CM 1

CRN 741272-40-2
 CMF C33 H28 Cd F10 N5 Pt
 CCI CCS

PAGE 1-A




PAGE 2-A



CM 2

CRN 14797-73-0

CMF Cl O4




IT 741272-43-5P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (mol. structure; preparation, structure, and optical properties of
 pentafluorophenyl complexes with a Pt-Cd bond)



RN 741272-43-5 CAPLUS

CN Platinum(1+), di-μ3-chlorodichlorotetrakis(pentafluorophenyl)bis[(1,4,7,
 10-tetraazacyclododecane-κN1,κN4,κN7,κN10)cadmium
]di-, stereoisomer (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



PAGE 3-A



PAGE 4-A



REFERENCE COUNT:

79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~LA~~ ANSWER 9 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 X
 ACCESSION NUMBER: 2004:433119 CAPLUS
 DOCUMENT NUMBER: 141:14233
 TITLE: Polyimide optical materials, their precursor solutions, and optical waveguide devices with low transmission loss
 INVENTOR(S): Kawamonzon, Yoshihiro; Nakayama, Toshio
 PATENT ASSIGNEE(S): Toshiba Corp., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004149711	A2	20040527	JP 2002-318239	20021031
US 2004197064	A1	20041007	US 2003-684474	20031015


PRIORITY APPLN. INFO.: JP 2002-318239 A 20021031

AB The optical materials, showing good heat and solvent resistance, comprise heterocyclic ring-containing polyimides preferably containing 5-40% F. The optical waveguide devices including the optical materials in core and/or cladding layers are useful for optical couplers, optical modulators, optical integrated circuits, etc.

IT **695185-76-3P 695185-78-5P 695185-80-9P**
 RL: DEV (Device component use); IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (heterocyclic ring-containing polyimide optical materials for optical waveguide devices with low transmission loss)


RN 695185-76-3 CAPLUS

CN Poly[(5,7-dihydro-1,3,5,7-tetraoxodipyrrolo[3,4-b:3',4'-e]pyrazine-2,6(1H,3H)-diyl) (2,4,5,6-tetrafluoro-1,3-phenylene)] (9CI) (CA INDEX NAME)




RN 695185-78-5 CAPLUS

CN Poly[(5,7-dihydro-1,3,5,7-tetraoxodipyrrolo[3,4-b:3',4'-e]pyrazine-2,6(1H,3H)-diyl) (2,2',3,3',5,5',6,6'-octafluoro[1,1'-biphenyl]-4,4'-diyl)] (9CI) (CA INDEX NAME)



RN 695185-80-9 CAPLUS

CN Poly[(5,7-dihydro-1,3,5,7-tetraoxodipyrrolo[3,4-b:3',4'-e]pyrazine-2,6(1H,3H)-diyl)(2,3,5,6-tetrafluoro-1,4-phenylene)oxy(2,3,5,6-tetrafluoro-1,4-phenylene)] (9CI) (CA INDEX NAME)



ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:874956 CAPLUS
 DOCUMENT NUMBER: 139:361001
 TITLE: Novel diabetes imaging probes
 INVENTOR(S): Yalpani, Manssur
 PATENT ASSIGNEE(S): Carbomer, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 23 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207823	A1	20031106	US 2003-411970	20030411
US 6911457	B2	20050628		
WO 2003086563	A2	20031023	WO 2003-US11034	20030411
WO 2003086563	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005522495	T2	20050728	JP 2003-583570	20030411
PRIORITY APPLN. INFO.:				
			US 2002-372717P	P 20020411
			WO 2003-US11034	W 20030411

OTHER SOURCE(S): MARPAT 139:361001


AB The present invention relates to novel imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiol. functions. Fluorinated antidiabetic compds. and their complexes with paramagnetic cations are used for evaluating the diabetes disease process and the mechanism of action of antidiabetic drugs by MRI.

IT 620609-95-2P

RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (diabetes imaging probes)

RN 620609-95-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[[[4-[[[4-[[[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]amino]carbonyl]-2,3,5,6-tetrafluorobenzoyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

X ANSWER 11 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:719481 CAPLUS
 DOCUMENT NUMBER: 139:254313
 TITLE: Gadolinium chelate oligomers, their use as contrast products in magnetic resonance imaging and their synthetic intermediates
 INVENTOR(S): Nachman, Isabelle; Port, Marc; Raynal, Isabelle; Rousseaux, Olivier
 PATENT ASSIGNEE(S): Guerbet SA, Fr.
 SOURCE: PCT Int. Appl., 122 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074523	A2	20030912	WO 2003-FR712	20030305
WO 2003074523	A3	20040325		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2836916	A1	20030912	FR 2002-2791	20020305
FR 2836916	B1	20040611		
EP 1480979	A2	20041201	EP 2003-727569	20030305
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			FR 2002-2791	A 20020305
			WO 2003-FR712	W 20030305

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns macrocyclic high-relaxivity gadolinium chelate oligomers of formula W-(A)_m, wherein W, A and m represent a wide variety of polynuclear gadolinium DOTA amide analogs, and their use as contrast products with vascular remanence for magnetic resonance imaging. Example compds., e.g., I, are prepared and exhibit strong relaxivity.

IT 596121-53-8P 596121-86-7P 596121-90-3P

596121-93-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of gadolinium chelate oligomers as contrast agents in magnetic resonance imaging)

RN 596121-53-8 CAPLUS


CN Gadolinium, [[1,1',1'',1''',1'''',1''''']-[13-(3-aminopropyl)-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-

$\kappa N3, \kappa N6, \kappa N9, \kappa N15$]tris[[4-(carboxy- κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]hexakis[1-deoxyhexitolato]](3-)]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A








RN 596121-86-7 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1'''''-[[13-[3-[[1,1-dimethylethoxy)carbonyl]amino]propyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15]tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)]bis[carbonyl[[2,3-dihydroxypropyl]imino]]]]hexakis[1-deoxyhexitolato]](3-)]-(9CI) (CA INDEX NAME)






PAGE 2-A




PAGE 2-B




RN 596121-90-3 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''']
 ''',1''''''''',1''''''''']-[[13-[3-[[(1,1-dimethylethoxy) carbonyl] amino
]propyl]-3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-
 triyl-κN3,κN6,κN9,κN15]tris[[4-(carboxy-κO)-
 1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-
 benzenetriyl)]bis(carboxynitrilo)]]dodecakis[1-deoxyhexitolato]](3-)]-
 (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A





RN 596121-93-6 CAPLUS


CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''']
 ''',1''''''''''',1''''''''''']-[13-(3-aminopropyl)-3,6,9,15-
 tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-
 κN3,κN6,κN9,κN15]tris[[4-(carboxy-κO)-1-oxo-
 4,1-butanediy]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-
 benzenetriyl)bis(carbonylnitrilo)]dodecakis[1-deoxyhexitolato]](3-)]-,
 mono(trifluoroacetate) (9CI) (CA INDEX NAME)



CM 1

CRN 596121-92-5


CMF C131 H205 Br9 Gd N17 078

CCI CCS






PAGE 2-A




PAGE 2-B



CM 2

CRN 76-05-1

CMF C2 H F3 02



LA ANSWER 12 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:659432 CAPLUS

DOCUMENT NUMBER: 138:299851

TITLE: Synthesis and evaluation of a monoreactive DOTA derivative for indium-111-based residualizing label to estimate protein pharmacokinetics

AUTHOR(S): Mukai, Takahiro; Namba, Shinji; Arano, Yasushi; Ono, Masahiro; Fujioka, Yasushi; Uehara, Tomoya; Ogawa, Kazuma; Konishi, Junji; Saji, Hideo

CORPORATE SOURCE: Department of Nuclear Medicine and Diagnostic Imaging, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

SOURCE: Journal of Pharmacy and Pharmacology (2002), 54(8), 1073-1081

CODEN: JPPMAB; ISSN: 0022-3573

PUBLISHER: Pharmaceutical Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of this study was to develop an indium-111 (¹¹¹In)-based residualizing label for estimating the pharmacokinetics of proteins. 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), which produced a highly stable and hydrophilic ¹¹¹In chelate, was selected as the chelating site, and the monoreactive DOTA derivative with a tetrafluorophenyl group as the protein binding site (mDOTA) was designed to avoid cross-linkings of proteins. mDOTA was synthesized with an overall yield of 11%. The stability in murine plasma, the radioactivity retention in the catabolic sites of proteins and the radiochem. yields of ¹¹¹In-labeled proteins via mDOTA were investigated using human serum albumin (HSA), galactosyl-neoglycoalbumin (NGA) and cytochrome c (cyt c) as model proteins. ¹¹¹In-labeled HSA via mDOTA was highly stable for 5 days after incubation in murine plasma. Long retention of radioactivity in the catabolic sites was observed after injection of ¹¹¹In-DOTA-NGA in mice, due to the slow elimination of the radiometabolite from the lysosome. At a chelator concentration of 42.2 μM, ¹¹¹In-DOTA-cyt c was produced with over 91% radiochem. yield. On the other hand, ¹¹¹In-DOTA-lysine and ¹¹¹In-DOTA were obtained with high radiochem. yields at lower chelator concns. These findings indicated that mDOTA would be an appropriate ¹¹¹In-labeling agent for estimating protein pharmacokinetics. These findings also suggested that the introduction of a protein binding site at a position distal from the unmodified DOTA structure would be preferable to preparing ¹¹¹In-DOTA-labeled proteins with higher specific activity.


IT 508181-48-4DP, protein conjugates

RL: DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(¹¹¹In-labeled DOTA derivative for estimating protein pharmacokinetics)

RN 508181-48-4 CAPLUS

CN Indium-111In, [mono(2,3,5,6-tetrafluorophenyl) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(3-)-κN1,κN4,κN7,κN10,κO4,κO7,κO10]-
(9CI) (CA INDEX NAME)




IT 277330-12-8P 508172-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(111In-labeled DOTA derivative for estimating protein pharmacokinetics)


RN 277330-12-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX NAME)



RN 508172-22-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, mono(2,3,5,6-tetrafluorophenyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:935597 CAPLUS
DOCUMENT NUMBER: 136:54028
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Rajopadhye, Milind; Barrett, John A.; Carpenter, Alan P., Jr.; Cheesman, Edward H.; Harris, Thomas D.
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 449 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098294	A2	20011227	WO 2001-US19794	20010621
WO 2001098294	A3	20030109		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2413957 AA 20011227 CA 2001-2413957 20010621 AU 2001070025 A5 20020102 AU 2001-70025 20010621 EP 1296678 A2 20030402 EP 2001-948554 20010621 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRIORITY APPLN. INFO.: US 2000-213212P P 20000621 WO 2001-US19794 W 20010621				

OTHER SOURCE(S): MARPAT 136:54028

AB Compds. (Q)d-Ln-(Ch)d' (Q is a residue having an indazole-type moiety, d = 1-10, d' = 1-100, Ln is a linking group, Ch is a metal-bonding unit) were prepared for use in the diagnosis and treatment of cancer. The present invention provides novel compds. useful for the treatment of rheumatoid arthritis. Thus, 2-[[[4-[4-[[[3-[2-[2-[3-[[6-[[1-aza-2-(2-sulfophenyl)vinyl]amino](3-pyridyl)]carbonylamino]propoxy]ethoxy]propyl]amino]sulfonyl]phenyl]phenyl]sulfonyl]amino]-3-[[1-[3-(indazole-2-ylamino)propyl](1H-indazol-5-yl)]carbonylamino]propanoic acid was prepared (claimed compound). Syntheses of radiopharmaceuticals, e.g., ^{99m}Tc(VnA) (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.


IT 277330-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of vitronectin receptor antagonist pharmaceuticals)

RN 277330-12-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX NAME)



10/780,887

~~LA~~ ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:881151 CAPLUS

DOCUMENT NUMBER: 134:36356

TITLE: Preparation of bicyclic polyamino carboxylic acid and amide metal complexes for use in medical imaging

INVENTOR(S): Port, Marc

PATENT ASSIGNEE(S): Guerbet SA, Fr.

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075141	A1	20001214	WO 2000-FR1591	20000608
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2794744	A1	20001215	FR 1999-7283	19990609
FR 2794744	B1	20010921		
CA 2376497	AA	20001214	CA 2000-2376497	20000608
BR 2000011436	A	20020305	BR 2000-11436	20000608
EP 1183255	A1	20020306	EP 2000-940473	20000608
EP 1183255	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103525	T2	20020521	TR 2001-200103525	20000608
US 6440956	B1	20020827	US 2000-589345	20000608
JP 2003501430	T2	20030114	JP 2001-502423	20000608
AT 233762	E	20030315	AT 2000-940473	20000608
PT 1183255	T	20030630	PT 2000-940473	20000608
ES 2188556	T3	20030701	ES 2000-940473	20000608
RU 2232763	C2	20040720	RU 2002-100125	20000608
NO 2001005991	A	20020206	NO 2001-5991	20011207
PRIORITY APPLN. INFO.:			FR 1999-7283	A 19990609
			WO 2000-FR1591	W 20000608
OTHER SOURCE(S):	MARPAT 134:36356			
GI				



AB The invention concerns metal chelates of bicyclic macrocycle 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene acid amide derivs. I [R = -Z-(C6H4Z')p-(C6H4Z'')q-C6R1R2R3R4R5; Z = bond, CH2, CH2CONH, (CH2)2NHCO; Z' = bond, O, S, NQ, CH2, CO, CONQ, NQCO, NQCONQ, CONQCH2CONQ; Z'' = bond, CONQ, NQCO, CONQCH2CONQ; p, q = 0-3; R1-R5 are independently H, Br, Cl, iodo, etc.; Q = H, C1-4 alkyl which may be mono- or polyhydroxylated]. Compds. I are useful as medical imaging agents (NMR, scintigraphy, x-ray). More specifically, gadolinium complexes of I are useful as NMR contrast agents. Metal chelates of macrocycle II and its salts are also claimed, including the gadolinium complex. A claimed process for the preparation of I involves reaction of 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene with R'O2CCHX(CH2)2CO2R' (X = leaving group, R' = H, C1-3 alkyl) and hydrolysis of the ester functions when R' ≠ H, followed by reaction with a metal salt or oxide to form the chelate, then reacting the chelate with an amine RNH2 in the presence of an agent to activate the carboxylic acid groups. E.g., a gadolinium(III) complex of 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-tri(α-glutaric acid) was prepared by this method.

IT 311772-48-2P 311772-49-3P 311772-50-6P

311772-51-7P 311772-52-8P 312280-07-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of metal chelates of tetraazabicyclopentadecatriene polyaminocarboxylates and amides as medical imaging agents)


RN 311772-48-2 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''',1''''',
''',1''''''''',1''''''''']-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-
1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tr
is[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-
ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis(carbonylnitrilo)]d
odecakis[1-deoxyhexitolato]](3-)]-(9CI)(CA INDEX NAME)



PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A









RN 311772-49-3 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1'''''-[(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]- (9CI) (CA INDEX NAME)









RN	311772-50-6	CAPLUS
CN	<p>Gadolinium, [[1,1',1'',1''',1'''',1'''''-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-5,1-butanediyl]iminomethylene-4,1-phenylenecarbonylimino(2,4,6-tribromo-5,1,3-benzenetriyl)bis(carbonyl[2,3-dihydroxypropyl]imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]-(9CI) (CA INDEX NAME)</p>	


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A




PAGE 2-B



PAGE 3-A




PAGE 3-B




RN 311772-51-7 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''',1''''',1''''',1''''',1''''',1''''']
-[(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-
1(15),11,13-triene-3,6,9-triyl-kN3,kN6,kN9,kN15)tr
is[[4-(carboxy-kO)-l-oxo-4,l-butanediyl]iminomethylene-4,1-
phenylenecarbonylimino(2,4,6-tribromo-5,1,3-benzenetriyl)bis(carbonylnitri
lo)]dodecakakis[1-deoxy-D-glucitolato]](3-)]-(9CI)-(CA INDEX NAME)


PAGE 1-A



PAGE 1-B





PAGE 1-C




PAGE 2-A

HO—

HO—CH₂—




PAGE 3-B





RN 311772-52-8 CAPLUS




CN Gadolinium, [[1,1',1'',1''',1'''',1''''',1''''''-[(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]iminomethylene-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino(2,4,6-tribromo-5,1,3-benzenetriyl)bis[carbonyl[(2,3-dihydroxypropyl)imino]]]]hexakis[1-deoxy-D-galactitolato]](3-)]- (9CI)
(CA INDEX NAME)

PAGE 1-A




—CH₂—OH


PAGE 1-D




PAGE 2-B



PAGE 3-B




PAGE 3-C




RN 312280-07-2 CAPLUS

CN Gadolinium, [[1,1',1'',1''',1'''',1'''''-(3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triyl-κN3,κN6,κN9,κN15)tris[[4-(carboxy-κO)-1-oxo-4,1-butanediyl]imino(1-oxo-2,1-ethanediyl)imino(2,4,6-tribromo-5,1,3-benzenetriyl)bis(carbonyl[(2,3-dihydroxypropyl)imino]])]hexakis[1-deoxy-D-glucitolato]](3-)]-(9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A



PAGE 2-B



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~LA~~ ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:420991 CAPLUS
 DOCUMENT NUMBER: 133:59098
 TITLE: Preparation of vitronectin receptor antagonist
 pharmaceuticals
 INVENTOR(S): Rajopadhye, Milind; Harris, Thomas David; Cheesman,
 Edward H.
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 362 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035488	A2	20000622	WO 1999-US30312	19991217
WO 2000035488	A3	20001109		
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6322770	B1	20011127	US 1999-281207	19990330
US 2002015680	A1	20020207	US 1999-281209	19990330
US 6524553	B2	20030225		
US 6548663	B1	20030415	US 1999-281050	19990330
CA 2346935	AA	20000622	CA 1999-2346935	19991217
AU 2000023715	A5	20000703	AU 2000-23715	19991217
EP 1140203	A2	20011010	EP 1999-967442	19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101775	T2	20020722	TR 2001-200101775	19991217
US 6794518	B1	20040921	US 1999-466588	19991217
US 2003124120	A1	20030703	US 2002-269252	20021011
US 2003149262	A1	20030807	US 2002-306054	20021126
US 2005154185	A1	20050714	US 2004-770380	20040202
PRIORITY APPLN. INFO.:			US 1998-112829P	P 19981218
			US 1998-80150P	P 19980331
			US 1998-112715P	P 19981218
			US 1998-112732P	P 19981218
			US 1998-112831P	P 19981218
			US 1999-281050	A3 19990330
			US 1999-281209	A3 19990330
			US 1999-466588	A3 19991217
			WO 1999-US30312	W 19991217

OTHER SOURCE(S): MARPAT 133:59098

AB Compds. (Q)d-Ln-Ch (Q is a residue having an indazole-type moiety, d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepared for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, 2-[[[4-[4-[[[3-[2-[2-[3-[[6-[[1-aza-2-(2-sulfophenyl)vinyl]amino](3-pyridyl)]carbonylamino]propoxy]ethoxy]ethoxy]propyl]amino]sulfonyl]phenyl]phenyl]sulfonyl]amino]-3-[[1-[3-(indazole-2-ylamino)propyl](1H-indazol-5-yl)]carbonylamino]propanoic acid was prepared (claimed compound). Syntheses

of radiopharmaceuticals, e.g., $^{99m}\text{Tc}(\text{VnA})$ (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.


IT **277330-12-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of vitronectin receptor antagonist pharmaceuticals)

RN 277330-12-8 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, tris(1,1-dimethylethyl) 2,3,5,6-tetrafluorophenyl ester (9CI) (CA INDEX NAME)




~~LA~~ ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:405857 CAPLUS
 DOCUMENT NUMBER: 131:214357
 TITLE: Synthesis of cyclenphosphoranes with polyfluorophenyl substituents; an X-ray structure of N-methyl cyclen-p-(heptafluorotolyl)phosphorane
 AUTHOR(S): Gupta, O. D.; Kirchmeier, Robert L.; Shreeve, Jeanine M.
 CORPORATE SOURCE: Department of Chemistry, University of Idaho, Moscow, ID, 83844-2343, USA
 SOURCE: Journal of Fluorine Chemistry (1999), 97(1-2), 223-228
 CODEN: JFLCAR; ISSN: 0022-1139
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

AB The metathesis reactions between the lithiated derivative of cyclenphosphorane I and octafluorotoluene, hexafluorobenzene, pentafluorobenzonitrile, pentafluoronitrobenzene, pentafluoro-n-butylbenzene, pentafluorobenzene and p-(cyanotetrafluorophenoxy-pentafluorobenzene) under reflux conditions gave cyclen-p-(heptafluorotolyl)phosphorane (3), cyclen-p-(pentafluorophenyl)phosphorane (4), cyclen-p-(cyanotetrafluorophenyl)phosphorane (5), cyclen-p-(tetrafluoronitrophenyl)phosphorane (6), cyclen-p-(n-butyltetrafluorophenyl)phosphorane (7), cyclen-p-(tetrafluorophenyl)phosphorane (8) and cyclen-p-(p-cyanotetrafluorophenoxytetrafluorophenyl)phosphorane (9), resp., in good yields. All products were characterized by spectral and anal. techniques. These materials are moderately stable thermally but are moisture sensitive, hydrolyzing to form cyclen phosphine oxide. Addition of CH₃I to 3 affords the phosphoammonium iodide which was characterized by x-ray crystal structure anal. The crystal is triclinic with a space group P1. The unit cell parameters a = 7.8652(2) Å, b = 8.584(2) Å, c = 22.1573(3) Å; α = 80.9010(10)°; β = 79.2490(10)°; γ = 76.9930(10)°; and Z = 2.

IT **242132-37-2P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)
 RN 242132-37-2 CAPLUS
 CN 8bH-4a,6a,8a-Triaza-2a-azonia-8bλ5-phosphapentaleno[1,6-cd]pentalene, octahydro-2a-methyl-8b-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]-, iodide, monohydrate, stereoisomer (9CI) (CA INDEX NAME)



● I⁻

IT 220130-39-2P 242132-32-7P 242132-33-8P


242132-34-9P 242132-35-0P 242132-36-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)


RN 220130-39-2 CAPLUS

CN 8bH-2a,4a,6a,8a-Tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalene, octahydro-8b-(pentafluorophenyl)- (9CI) (CA INDEX NAME)




RN 242132-32-7 CAPLUS

CN Benzonitrile, 2,3,5,6-tetrafluoro-4-(octahydro-8bH-2a,4a,6a,8a-tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalen-8b-yl)- (9CI) (CA INDEX NAME)




RN 242132-33-8 CAPLUS

CN 8bH-2a,4a,6a,8a-Tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalene,
octahydro-8b-(2,3,5,6-tetrafluoro-4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 242132-34-9 CAPLUS


CN 8bH-2a,4a,6a,8a-Tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalene,
8b-(4-butyl-2,3,5,6-tetrafluorophenyl)octahydro- (9CI) (CA INDEX NAME)



RN 242132-35-0 CAPLUS


CN 8bH-2a,4a,6a,8a-Tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalene,

octahydro-8b-(2,3,5,6-tetrafluorophenyl)- (9CI) (CA INDEX NAME)



RN 242132-36-1 CAPLUS

CN Benzonitrile, 2,3,5,6-tetrafluoro-4-[2,3,5,6-tetrafluoro-4-(octahydro-8bH-2a,4a,6a,8a-tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalen-8b-yl)phenoxy]- (9CI) (CA INDEX NAME)




IT 242132-31-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, hydrolysis, and reaction with Me iodide)

RN 242132-31-6 CAPLUS

CN 8bH-2a,4a,6a,8a-Tetraaza-8bλ5-phosphapentaleno[1,6-cd]pentalene, octahydro-8b-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

26


THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~LA~~ ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:708316 CAPLUS
 DOCUMENT NUMBER: 130:139391
 TITLE: Reactions of tetracyclic tetraaminophosphoranes with dichloroperfluoro cyclic and acyclic alkenes and halo compounds
 AUTHOR(S): Gupta, O. D.; Kirchmeier, Robert L.; Shreeve, Jean'ne M.
 CORPORATE SOURCE: Department of Chemistry, University of Idaho, Moscow, ID, 83843, USA
 SOURCE: Journal of Fluorine Chemistry (1998), 92(2), 147-151
 CODEN: JFLCAR; ISSN: 0022-1139
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

- AB Cyclenphosphorane, e.g. I, was reacted with 1,2-dichlorotetrafluorocyclobutene-1, 1,2-dichlorohexafluorocyclopentene-1, 1,2-dichlorooctafluorocyclohexene-1, iodopentafluorobenzene, 2-iodo-1,1,1-trifluoroethane, and 2,3-dichlorohexafluorobutene-2 in the presence of triethylamine at room temperature in THF to form monochlorotetrafluorocyclobutenylcyclenphosphorane, monochlorohexafluorocyclopentenylcyclenphosphorane, monochlorooctafluorocyclohexenylcyclenphosphorane, pentafluorophenylcyclenphosphorane, 1,1,1-trifluoroethylcyclenphosphorane, and 2-chlorohexafluorobut-2-enylcyclenphosphorane in 70-80% yields, resp. Cyclamphosphine oxide reacted with dichloroperfluoro cyclic alkenes in the presence of triethylamine in chloroform to form N-(chlorotetrafluorocyclobutenyl)cyclamphosphine oxide, N-(chlorohexafluorocyclopentyl)cyclamphosphine oxide and N-(chlorooctafluorocyclohexenyl)-cyclamphosphine oxide in .apprx.50% yields, resp. These moisture sensitive cyclamphosphine oxide derivs. are stable and are soluble in CHCl₃, CH₃CN and DMSO.
- IT **220130-39-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
- RN 220130-39-2 CAPLUS
 CN 8bH-2a, 4a, 6a, 8a-Tetraaza-8bλ⁵-phosphapentaleno[1,6-cd]pentalene, octahydro-8b-(pentafluorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


X ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:155211 CAPLUS
 DOCUMENT NUMBER: 124:305463
 TITLE: A new approach to hepatospecific MRI contrast agents: gadolinium complexes conjugated to iodinated synthons
 AUTHOR(S): Anelli, Pier Lucio; Calabi, Luisella; de Haen, Christoph; Fedeli, Franco; Losi, Pietro; Murru, Marcella; Uggeri, Fulvio
 CORPORATE SOURCE: Centro Ricerche Milano, Bracco S.p.A., Milan, I-20134, Italy
 SOURCE: Gazzetta Chimica Italiana (1996), 126(2), 89-97
 CODEN: GCITA9; ISSN: 0016-5603
 PUBLISHER: Societa Chimica Italiana
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The use of biliary iodinated x-ray contrast agents as an address moiety to transport Gd complexes into hepatocytes was studied. Conjugates containing a Gd chelating subunit (tetraazacyclododecanetetraacetic acid and diethylenetetraaminepentaacetic acid) and an iodinated subunit were designed and synthesized. This series takes into account structural features such as: nature of the iodinated address moiety, overall charge of the conjugate and distance between the two subunits. Preliminary physicochem. and pharmacol. screenings show, for conjugates in which the Gd complex is linked through a spacer to a unit of iopanoic acid: (i) r_1 values of >18 (mM s)⁻¹ in human serum, reflecting a strong interaction with human serum albumin; (ii) biliary elimination in rats $>65\%$. Iopanoic acid can be used successfully as an address for the preparation of conjugates which are promising candidates as hepatospecific MRI contrast agents.

IT **160982-31-0P 160982-32-1P 160982-33-2P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (for preparation of gadolinium MRI contrast agents)

RN 160982-31-0 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 160982-32-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(3-carboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 160982-33-2 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-
(9CI) (CA INDEX NAME)




IT 160982-30-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(for preparation of gadolinium MRI contrast agents and protonation consts.)

RN 160982-30-9 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



IT 160982-43-4P 160982-44-5P 175732-27-1P


175732-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(for preparation of ligands for gadolinium MRI contrast agents)

RN 160982-43-4 CAPLUS

CN Benzoic acid, 2,4,6-triiodo-3-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 160982-44-5 CAPLUS

CN Benzenepropanoic acid, α -ethyl-2,4,6-triiodo-3-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]- (9CI) (CA INDEX NAME)


RN 175732-27-1 CAPLUS

CN Benzoic acid, 2,4,6-triiodo-3-[[1-oxo-6-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]hexyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 2-A




RN 175732-28-2 CAPLUS

CN Benzenepropanoic acid, α -ethyl-2,4,6-triiodo-3-[[1-oxo-6-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]hexyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT 175732-19-1P 175732-21-5P 175732-23-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and toxicity as MRI contrast agent)

RN 175732-19-1 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, [10-[2-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)]gadolate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 175732-18-0

CMF C27 H34 Gd I3 N5 O9 . H

CCI CCS




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 175732-21-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [10-[2-[[6-[(3-carboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)]gadolate(1-) (9CI) (CA INDEX NAME)

CM 1

10/780,887

CRN 175732-20-4
CMF C29 H37 Gd I3 N6 O10 . H
CCI CCS




● H⁺

CM 2

CRN 6284-40-8
CMF C7 H17 N O5


Absolute stereochemistry.



RN 175732-23-7 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, [10-[2-[[6-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)]gadolate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 175732-22-6
CMF C33 H45 Gd I3 N6 O10 . H
CCI CCS




● H^+

CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



IT **175732-15-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and toxicity as MRI contrast agent and stability constant)

RN 175732-15-7 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, [10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(4-)]gadolinatate(1-) (9CI) (CA INDEX NAME)

CM 1

CRN 175732-14-6

CMF C23 H26 Gd I3 N5 O9 . H

CCI CCS




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



10/780,887

ANSWER 19 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:787155 CAPLUS

DOCUMENT NUMBER: 123:198842

TITLE: Preparation of iodinated oligomeric compounds and their diagnostic compositions

INVENTOR(S): Anelli, Pier Lucio; Brocchetta, Marino; De Haen, Christoph; Gazzotti, Ornella; Uggeri, Fulvio; Verona, Sandra; Visigalli, Massimo

PATENT ASSIGNEE(S): Dibra S.p.A., Italy; Bracco S.p.A.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9501966	A1	19950119	WO 1994-EP2111	19940629
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9471251	A1	19950206	AU 1994-71251	19940629
EP 707572	A1	19960424	EP 1994-920471	19940629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08512297	T2	19961224	JP 1994-503801	19940629
ZA 9404923	A	19950314	ZA 1994-4923	19940707
PRIORITY APPLN. INFO.:			IT 1993-MI1479	A 19930708
			WO 1994-EP2111	W 19940629
OTHER SOURCE(S):	MARPAT 123:198842			
GI				



AB Title compds. I (l = 2-20; m = 1-100; n = 0-2; A = aliphatic heterocyclyl, aromatic and carries 2-20 groups B or 2-20 org.residues ending with B; B = bond, CO, NHCO2, NHCONH, O, S, O2S, PO2, SO3, PO3, SO2NH SO, PO, etc.; L = I3C6PQ wherein P, Q = XO, R3NRCO, R4CONR wherein R, R3 = H, (substituted) C1-6 alkyl, R4 = C1-20 cyclyl or acyclyl, etc., X = neg. charge, etc.; M = substituted triiodophenyl moiety) are prepared as contrast agents particularly useful for X-ray diagnostic exams. of vascular system of the human and animal body. No compns. comprising I are given. To octahydro-1H-1,4,7-triazonine in DMF was added (S)-3-[2-(acetyloxy)-1-oxopropyl]amino-5-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]carbonyl]-2,4,6-triiodobenzoyl chloride to give after workup the title compound 3.3'3''-[(hexahydro-1H-1,4,7-triazonin-1,4,7-triyl)tricarboxyl]tris[N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(S)-(3-hydroxy-1-oxopropyl)amino]-2,4,6-triiodobenzamide] and its dicarbonyl analog.

IT 167629-97-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of iodinated oligomeric compds. and their diagnostic compns.)


RN 167629-97-2 CAPLUS

CN Benzamide, 3,3',3''-(1,4,7,10-tetraazacyclododecane-1,4,7-triyltricarboxyl)tris[N-[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-, [1(S)-[1(R*),4(R*),7(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





~~LA~~ ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:358851 CAPLUS

DOCUMENT NUMBER: 122:299161

TITLE: Iodinated paramagnetic chelates and their use as contrast agents

INVENTOR(S): Uggeri, Fulvio; Anelli, Pier Lucio; Fedeli, Franco; Murru, Marcella; De Haen, Christoph

PATENT ASSIGNEE(S): Dibra S.p.A., Italy; Bracco S.p.A.

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427644	A1	19941208	WO 1994-EP1677	19940525
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9469965	A1	19941220	AU 1994-69965	19940525
EP 703790	A1	19960403	EP 1994-918782	19940525
EP 703790	B1	20000816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08510458	T2	19961105	JP 1995-500213	19940525
AT 195432	E	20000915	AT 1994-918782	19940525
ZA 9403816	A	19950131	ZA 1994-3816	19940601
US 5660814	A	19970826	US 1995-448476	19950530
PRIORITY APPLN. INFO.:			IT 1993-MI1155	A 19930602
			IT 1993-MI1274	A 19930615
			WO 1994-EP1677	W 19940525

OTHER SOURCE(S): MARPAT 122:299161

AB The capacity of paramagnetic metal chelates to influence proton relaxation times during NMR imaging is enhanced by attaching to the chelating part of the mol. a polyiodinated component including at least a triiodinated aromatic or heteroarom. x-ray opaque residue. Gadolinium complexes of some.

IT 160982-30-9P 160982-37-6P 160982-43-4P


160982-44-5P 160982-45-6P 160982-48-9P

RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polyiodinated paramagnetic lanthanide chelates as NMR imaging contrast agents)

RN 160982-30-9 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 160982-37-6 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-6-oxohexyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 160982-43-4 CAPLUS

CN Benzoic acid, 2,4,6-triiodo-3-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]- (9CI) (CA INDEX NAME)



RN 160982-44-5 CAPLUS


CN Benzenepropanoic acid, α-ethyl-2,4,6-triiodo-3-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]- (9CI) (CA INDEX NAME)




RN 160982-45-6 CAPLUS

CN Benzoic acid, 2,4,6-triiodo-3-[[1-oxo-6-[(1,4,7,10-tetraazacyclododec-1-ylacetyl)amino]hexyl]amino]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A







● 3 HCl


RN 160982-48-9 CAPLUS

CN Benzenepropanoic acid, α -ethyl-2,4,6-triiodo-3-[[1-oxo-6-[[1-oxo-3-(phenylmethoxy)-2-(1,4,7,10-tetraazacyclododec-1-yl)propyl]amino]hexyl]amino]- (9CI) (CA INDEX NAME)






- IT **160982-30-9DP**, gadolinium complexes **160982-31-0DP**, lanthanide complexes **160982-32-1DP**, gadolinium complexes **160982-33-2DP**, gadolinium complexes **160982-34-3DP**, gadolinium complexes **160982-37-6DP**, gadolinium complexes
 RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of polyiodinated paramagnetic lanthanide chelates as NMR imaging contrast agents)
- RN 160982-30-9 CAPLUS
- CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(3-carboxy-2,4,6-triiodophenyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




- RN 160982-31-0 CAPLUS
- CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 160982-32-1 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(3-carboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 160982-33-2 CAPLUS


CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-6-oxohexyl]amino]-2-oxoethyl]-
(9CI) (CA INDEX NAME)




RN 160982-34-3 CAPLUS

CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[(3,5-dicarboxy-2,4,6-triiodophenyl)amino]-6-oxohexyl]amino]-2-oxoethyl]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 160982-37-6 CAPLUS
CN 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[[6-[[3-(2-carboxybutyl)-2,4,6-triiodophenyl]amino]-6-oxohexyl]amino]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]- (9CI) (CA INDEX NAME)

